Nuochengjianhua (688428.SH): Obutinib's phase IIb study on systemic lupus erythematosus reached the main end

Zhitong Finance App News, Nuocheng Jianhua (688428.SH) announced that the phase IIb clinical study of the BTK inhibitor obutinib to treat systemic lupus erythematosus (“SLE”) independently developed by the company reached the main end, and was approved by the National Drug Administration (NMPA) Drug Evaluation Center (CDE) to carry out phase III registered clinical trials. The company will begin this clinical study as soon as possible.

Clinical IIb results showed that obutinib showed excellent efficacy, good tolerability, and safety in patients receiving treatment for 48 weeks.